论文部分内容阅读
近期在纽约召开的药物对脂质代谢的影响的会议上，Andrx公司公布了有关洛伐他汀缓释制剂（商品名：Altocor）的临床研究数据。Altocor为默克公司在美国市场独占权2001年到期的洛伐他汀（lovastatin）的长效制剂，是Andrx公司首个自主开发的品牌产品。公司计划2002年3月提交新药
At a recent meeting in New York on the effects of drugs on lipid metabolism, Andrx released clinical data on lovastatin extended-release formulations (trade name: Altocor). Altocor is the long-acting formulation of lovastatin, a product of Merck’s US market monopoly due in 2001. It is Andrx’s first self-developed branded product. The company plans to submit new drugs in March 2002